Join
Live feed
·
PRReleasevia Quantisnow
Processa Pharmaceuticals Inc. logo

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

ByQuantisnow·Wall Street's wire, on your screen.
PCSA· Processa Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PCSA (Processa Pharmaceuticals Inc.) and more on Quantisnow.